BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report
22.1.2025 10:00:00 EET | Business Wire | Press release
BON CHARGE, a global leader in premium wellness technology, today announces the release of its inaugural Global Red Light Therapy Trend Report, showcasing how red light therapy is fast becoming a cornerstone of modern wellness routines. Based on a global survey of 7,000 adults across the U.S., UK, UAE, and Australia, the report highlights the rising adoption of red light therapy, particularly among younger consumers, with the UAE leading with seven in ten adults actively using red light therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122177591/en/
BON CHARGE Unveils First-Ever Global Red Light Therapy Trend Report (Photo: Business Wire)
Coinciding with the release, BON CHARGE debuts its brand refresh, including a redesigned website. This emphasizes BON CHARGE’s mission to simplify wellness by offering the world’s widest range of wellness products on a single, easy-to-access platform, empowering individuals to prioritize their self-care with science-backed technology solutions.
“As consumers become increasingly interested in their overall wellness, they are searching for accessible tools that offer multiple benefits, making red light therapy a game-changer,” said Katie Mant, Co-Founder of BON CHARGE. “Our research underscores its impact on key areas like skin appearance, sleep, and recovery, showcasing its role in shaping the future of proactive wellness worldwide.”
Red Light Therapy: A Global Trend in Wellness
The BON CHARGE Global Red Light Therapy Trend Report provides key insights into how this emerging technology is reshaping global wellness routines:
- UAE Leading the Way: Red light therapy has gained remarkable traction in the UAE, where 70% of adults report using it—far exceeding adoption rates in other markets. Nearly a third (30%) use it monthly, underscoring its popularity as a regular wellness practice.
- Younger Generations Drive Adoption: Across all surveyed markets, adults aged 18-34 are the most engaged users of red light therapy, with standout adoption rates of 77% in the UAE, 53% in the U.S. and Australia, and 46% in the UK.
- A Recent Addition to Wellness Routines: Red light therapy is still a relatively new addition for many users, with two-thirds globally reporting they started in the past two years. Younger adults (18-34) are driving this trend, with 73% of users in the UK, 70% in the UAE and 71% in the U.S. and Australia having adopted the practice recently.
- Top Device of Choice: Red light face masks lead globally as the most popular device, chosen by around a third of users (35% in the UAE, 34% in Australia, 36% in the UK and 27% in the U.S.). Note: Preferences vary by region with devices to soothe joint stiffness taking the lead in the UK and U.S. (38% and 30%, respectively).
Regional Insights Reflect Diverse Motivations
Red light therapy is a growing phenomenon. While muscle and joint relaxation is the top reason for use globally, regional nuances reveal additional motivations behind its widespread appeal:
- United Arab Emirates: The UAE sets the pace for global adoption with nearly 70% of adults engaged with red light therapy. A greater understanding of red light therapy and professional endorsements drive this trend, with 37% of users recommended by a skin specialist.
- Australia: Australians cite sleep improvement and skincare benefits as key reasons for use, after muscle and joint relaxation, and well over half (61%) have adopted red light therapy within the past two years.
- United States: Adoption is stronger among men than women in the United States, with nearly 40% reporting usage. Improved sleep and mood are cited as key motivators (28% and 24%, respectively) by users, highlighting the growing focus on recovery and mental well-being.
- United Kingdom: While adoption lags behind other markets, red light therapy is rapidly gaining traction among younger adults, with 73% of users aged 18-34 starting in the last two years. With lead motivation for use being skincare benefits, following muscle and joint relaxation.
“This report reflects a global movement toward proactive wellness,” said Andy Mant, Co-Founder of BON CHARGE. “Red light therapy’s rapid adoption, particularly among younger generations, signals a significant shift. As science continues to validate its benefits, we believe it will become as essential to wellness as nutrition and fitness.”
Explore the Full Report and Press Kit
Access the BON CHARGE Global Red Light Therapy Global Trend Report and explore key findings, visual assets, and additional resources in our digital press kit. Visit boncharge.com to download the report and learn more about BON CHARGE’s pioneering wellness solutions.
Notes to Editors
Research of 7,000 adults across the UK, USA, UAE, and Australia by Opinium Research in December 2024.
About BON CHARGE
Founded in 2017 by Katie and Andy Mant, BON CHARGE is setting new standards in simplifying wellness by offering the widest range of science-backed technology solutions to help individuals navigate their wellness journeys. The brand celebrates wellness as a continuous journey, honoring individuality and inspiring growth through community and shared knowledge. From sleep and recovery to beauty and mental well-being, BON CHARGE is a trusted partner in proactive self-care. Headquartered in Perth, Australia, every product is rooted in rigorous scientific research and designed to help individuals in achieving their wellness goals. For more information, visit boncharge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122177591/en/
Contacts
Press Contact
Jack Taylor PR
boncharge@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom